We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Read MoreHide Full Article
Key Takeaways
NTLA is advancing lonvo-z in HAE toward a potential 2027 launch if approved, getting its first product.
FDA recently granted priority review to lonvo-z's BLA, with a decision expected on March 10, 2027.
NTLA's nex-z is in two late-stage studies that could aid global regulatory filings if results are positive.
Intellia Therapeutics (NTLA - Free Report) leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates.
The company has been making decent progress with the advancement of its two pipeline candidates, lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) and nex-z (formerly NTLA-2001) for transthyretin (ATTR) amyloidosis.
Earlier this month, the FDA accepted and granted priority review to the biologics license application (BLA) seeking approval for lonvo-z, an in vivo CRISPR-based gene-editing therapy, for the treatment of HAE.
A final decision on the BLA from the regulatory body is expected on March 10, 2027.
HAE is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin. If approved, lonvo-z will become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
In April 2026, Intellia reported positive top-line results from the global phase III HAELO study evaluating lonvo-z in HAE.
The company plans to commercially launch lonvo-z in the first half of 2027, upon potential approval in the United States. If approved and successfully commercialized, lonvo-z could significantly strengthen Intellia’s growth prospects by providing its first commercial product and a potential new revenue stream.
Besides lonvo-z, Intellia’s other pipeline candidate, nex-z, a CRISPR-based gene-edited therapy, is being developed in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The company’s top line currently comprises only collaboration revenues from its partners, like Regeneron and others.
Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively. If the data from the studies are found to be positive, it should likely enable global regulatory filings for nex-z. The successful development of nex-z could provide impetus to the stock and create long-term growth visibility.
However, any regulatory or developmental setback related to ongoing studies will be a major setback for Intellia. Growing competition in the target market also remains a worry.
NTLA's Competition in the Target Market
Intellia’s pipeline candidates are likely to face competition from other companies that are leveraging CRISPR/Cas9 gene-editing technology to target diseases across similar therapeutic areas.
CRISPR Therapeutics (CRSP - Free Report) is the first company in the world to market a CRISPR/Cas9-based therapy. CRSP’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease and transfusion-dependent beta-thalassemia.
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization.
Beam Therapeutics (BEAM - Free Report) is developing its leading ex-vivo genome-editing candidate, risto-cel (formerly BEAM-101), in the phase I/II BEACON study for the treatment of patients with SCD. BEAM plans to submit a BLA for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively.
NTLA's Price Performance, Valuation and Estimates
Year to date, shares of Intellia have rallied 36.4% compared with the industry’s increase of 6.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 2.35, lower than 3.87 for the industry. The stock is trading below its five-year mean of 2.50.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2026 loss per share has widened from $3.18 to $3.21 over the past 60 days. Meanwhile, loss per share estimates for 2027 have widened from 68 cents to $2.32 during the same time frame.
View the Zacks #1 Rank List
Image: Bigstock
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Key Takeaways
Intellia Therapeutics (NTLA - Free Report) leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates.
The company has been making decent progress with the advancement of its two pipeline candidates, lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) and nex-z (formerly NTLA-2001) for transthyretin (ATTR) amyloidosis.
Earlier this month, the FDA accepted and granted priority review to the biologics license application (BLA) seeking approval for lonvo-z, an in vivo CRISPR-based gene-editing therapy, for the treatment of HAE.
A final decision on the BLA from the regulatory body is expected on March 10, 2027.
HAE is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin. If approved, lonvo-z will become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
In April 2026, Intellia reported positive top-line results from the global phase III HAELO study evaluating lonvo-z in HAE.
The company plans to commercially launch lonvo-z in the first half of 2027, upon potential approval in the United States. If approved and successfully commercialized, lonvo-z could significantly strengthen Intellia’s growth prospects by providing its first commercial product and a potential new revenue stream.
Besides lonvo-z, Intellia’s other pipeline candidate, nex-z, a CRISPR-based gene-edited therapy, is being developed in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The company’s top line currently comprises only collaboration revenues from its partners, like Regeneron and others.
Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively. If the data from the studies are found to be positive, it should likely enable global regulatory filings for nex-z. The successful development of nex-z could provide impetus to the stock and create long-term growth visibility.
However, any regulatory or developmental setback related to ongoing studies will be a major setback for Intellia. Growing competition in the target market also remains a worry.
NTLA's Competition in the Target Market
Intellia’s pipeline candidates are likely to face competition from other companies that are leveraging CRISPR/Cas9 gene-editing technology to target diseases across similar therapeutic areas.
CRISPR Therapeutics (CRSP - Free Report) is the first company in the world to market a CRISPR/Cas9-based therapy. CRSP’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease and transfusion-dependent beta-thalassemia.
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization.
Beam Therapeutics (BEAM - Free Report) is developing its leading ex-vivo genome-editing candidate, risto-cel (formerly BEAM-101), in the phase I/II BEACON study for the treatment of patients with SCD. BEAM plans to submit a BLA for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively.
NTLA's Price Performance, Valuation and Estimates
Year to date, shares of Intellia have rallied 36.4% compared with the industry’s increase of 6.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 2.35, lower than 3.87 for the industry. The stock is trading below its five-year mean of 2.50.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2026 loss per share has widened from $3.18 to $3.21 over the past 60 days. Meanwhile, loss per share estimates for 2027 have widened from 68 cents to $2.32 during the same time frame.
Image Source: Zacks Investment Research
NTLA's Zacks Rank
Intellia currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.